Business
Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer InitiatedIND and Phase 1a Study for NXP900 PendingIn-Vivo Data Presented by
About this update from Nuvectis Pharma, Inc.
[{"type":"text","content":"Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer InitiatedIND and Phase 1a Study for NXP900 PendingIn-Vivo Data Presented by Investigators from the Mayo Clinic at the AACR Conference Demonstrates Potential of NXP800 in the Treatment of Cholangiocarcinoma FORT LEE, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (\"Nuvectis\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the first quarter 2023 and provided an update on recent business progress. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis commented, \"In the last few months, the Nuvectis team accomplished several important milestones that significantly advance our NXP800 and NXP900 development programs. For NXP800, we initiated the Phase 1b study, in which the preliminary efficacy of NXP800 in a target population, in this case platinum-resistant, ARID1a-mutated ovarian carcinoma, will be evaluated for the first time. The study is a multicenter, open label, single-arm clinical trial that will be conducted in the United States, United Kingdom and Europe, in collaboration with the GOG Foundation and the European Network of Gynecological Oncological Trial Group (“ENGOT”), two of the world's premier gynecology oncology clinical trials consortia. The Phase 1b study follows the preliminary safety, tolerability and dosing findings from the Phase 1a in advanced solid tumors.\" Mr. Bentsur continued, \"For NXP900, the Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) is pending and we’re preparing to commence the first-in-human clinical trial shortly after the IND becomes effective. Lastly, recent publications for both NXP800 and NXP900 provided substantial scientific evidence for additional clinical development opportunities, including recent data from patient-derived xenograft (“PDX”) in vivo models presented at this year’s American Association for Cancer Research annual meeting (“AACR”) by investigators from the Mayo Clinic that demonstrated the potential of NXP800 to treat cholangiocarcinoma, a deadly disease for which only limited treatment options exist and new treatment opti...